| Literature DB >> 30959471 |
Daniel G Coit1, John A Thompson2, Mark R Albertini3, Christopher Barker1, William E Carson4, Carlo Contreras5, Gregory A Daniels6, Dominick DiMaio7, Ryan C Fields8, Martin D Fleming9, Morganna Freeman10, Anjela Galan11, Brian Gastman12, Valerie Guild13, Douglas Johnson14, Richard W Joseph15, Julie R Lange16, Sameer Nath17, Anthony J Olszanski18, Patrick Ott19, Aparna Priyanath Gupta20, Merrick I Ross21, April K Salama22, Joseph Skitzki23, Jeffrey Sosman20, Susan M Swetter24, Kenneth K Tanabe25, Evan Wuthrick26, Nicole R McMillian27, Anita M Engh27.
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.Entities:
Year: 2019 PMID： 30959471 DOI： 10.6004/jnccn.2019.0018
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908